Oseroff AR - Search Results

1

A dose ranging study of photodynamic therapy with porfimer sodium (Photofrin) for treatment of basal cell carcinoma.

Oseroff AR, Blumenson LR, Wilson BD, Mang TS, Bellnier DA, Parsons JC, Frawley N, Cooper M, Zeitouni N, Dougherty TJ. Oseroff AR, et al. Lasers Surg Med. 2006 Jun;38(5):417-26. doi: 10.1002/lsm.20363. Lasers Surg Med. 2006. PMID: 16788928 Clinical Trial.

2

Mild skin photosensitivity in cancer patients following injection of Photochlor (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a; HPPH) for photodynamic therapy.

Bellnier DA, Greco WR, Nava H, Loewen GM, Oseroff AR, Dougherty TJ. Bellnier DA, et al. Among authors: oseroff ar. Cancer Chemother Pharmacol. 2006 Jan;57(1):40-5. doi: 10.1007/s00280-005-0015-6. Epub 2005 Nov 5. Cancer Chemother Pharmacol. 2006. PMID: 16001178 Clinical Trial.

3

Clinical pharmacokinetics of the PDT photosensitizers porfimer sodium (Photofrin), 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (Photochlor) and 5-ALA-induced protoporphyrin IX.

Bellnier DA, Greco WR, Loewen GM, Nava H, Oseroff AR, Dougherty TJ. Bellnier DA, et al. Among authors: oseroff ar. Lasers Surg Med. 2006 Jun;38(5):439-44. doi: 10.1002/lsm.20340. Lasers Surg Med. 2006. PMID: 16634075

4

Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.

Bellnier DA, Greco WR, Loewen GM, Nava H, Oseroff AR, Pandey RK, Tsuchida T, Dougherty TJ. Bellnier DA, et al. Among authors: oseroff ar. Cancer Res. 2003 Apr 15;63(8):1806-13. Cancer Res. 2003. PMID: 12702566

5

Photodynamic therapy for nonmelanoma skin cancers. Current review and update.

Zeitouni NC, Oseroff AR, Shieh S. Zeitouni NC, et al. Among authors: oseroff ar. Mol Immunol. 2003 Jul;39(17-18):1133-6. doi: 10.1016/s0161-5890(03)00083-x. Mol Immunol. 2003. PMID: 12835091 Review.

6

Treatment of diffuse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5-aminolevulinic acid photodynamic therapy.

Oseroff AR, Shieh S, Frawley NP, Cheney R, Blumenson LE, Pivnick EK, Bellnier DA. Oseroff AR, et al. Arch Dermatol. 2005 Jan;141(1):60-7. doi: 10.1001/archderm.141.1.60. Arch Dermatol. 2005. PMID: 15655143

7

Nature: a rich source for developing multifunctional agents. Tumor-imaging and photodynamic therapy.

Pandey RK, Goswami LN, Chen Y, Gryshuk A, Missert JR, Oseroff A, Dougherty TJ. Pandey RK, et al. Lasers Surg Med. 2006 Jun;38(5):445-67. doi: 10.1002/lsm.20352. Lasers Surg Med. 2006. PMID: 16788930 Review.

8

An assay for the quantitation of Photofrin in tissues and fluids.

Bellnier DA, Greco WR, Parsons JC, Oseroff AR, Kuebler A, Dougherty TJ. Bellnier DA, et al. Among authors: oseroff ar. Photochem Photobiol. 1997 Aug;66(2):237-44. doi: 10.1111/j.1751-1097.1997.tb08649.x. Photochem Photobiol. 1997. PMID: 9277143

9

Photofrin photodynamic therapy for treatment of AIDS-related cutaneous Kaposi's sarcoma.

Bernstein ZP, Wilson BD, Oseroff AR, Jones CM, Dozier SE, Brooks JS, Cheney R, Foulke L, Mang TS, Bellnier DA, Dougherty TJ. Bernstein ZP, et al. Among authors: oseroff ar. AIDS. 1999 Sep 10;13(13):1697-704. doi: 10.1097/00002030-199909100-00013. AIDS. 1999. PMID: 10509571 Clinical Trial.

10

Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate.

Henderson BW, Busch TM, Vaughan LA, Frawley NP, Babich D, Sosa TA, Zollo JD, Dee AS, Cooper MT, Bellnier DA, Greco WR, Oseroff AR. Henderson BW, et al. Among authors: oseroff ar. Cancer Res. 2000 Feb 1;60(3):525-9. Cancer Res. 2000. PMID: 10676629

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

106 results

Search Page

Filters